Tackling the Issues: Caring for HIV-Positive Women Today
|
|
- Abigail Baker
- 5 years ago
- Views:
Transcription
1 Tackling the Issues: Caring for HIV-Positive Women Today Anna Maria Geretti University of Liverpool 2 nd CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV - BUCHAREST, ROMANIA 6-7 OCTOBER 2016
2 Women as Share of People Living with HIV by Region, 2014 ( 15 years of age) HIV is the leading cause of death in women aged yrs Young women who experience partner violence 50% more likely to have HIV than women who do not report partner violence UNAIDS HOW AIDS Changed Everything 2015
3 UNAIDS HOW AIDS Changed Everything 2015
4 Proportion of Women enrolled in HIV Trials ALERT GEMINI ESS30009 ASSERT GS 934 ARIES ARTEN STARTMRK GS 903 CNA30024 THRIVE ARTEMIS ECHO HEAT MERIT ACTG 5905 AI KLEAN CASTLE ACTG 384 ACTG 5202 Proportion of Women in Clinical Trials 27% women 78% women GRACE WAVES Percent of Women enrolled (%) Percentage of recruited women apted from Slide courtesy Michelle Giles
5 Potential Impact of Gender in HIV Infection BIOLOGY TREATMENT PSYCHO-SOCIAL RESEARCH NEEDS Susceptibility, immune activation, disease progression, compartmentalization, pregnancy, hormones PK/PD, drug toxicity and tolerability, virological outcomes Testing, access to care, retention in care, mental health and well-being, internalised stigma, gender-based violence, neighbourhood, food security, housing Equity of access, support, treatment, cure Loutfy et al. AIDS Soc 2013; Rosin et al. HIV Med 2015; Gueler et al. AIDS 2015; Johnston et al. AIDS Res Human Retrovir 2015; Hatcher et al. AIDS 2015
6 Gender: Pre-ART Profile Women with and without HIV have higher CD4 counts than man (Main et al 1996; Delmas et al 1997) Adjusted for CD4 count, women have lower viral load than men (Sterling et al. 2001; Law et al. 2015) No difference in disease progression despite CD4 count and viral load differences (Napravnik et al. 2002; Sterling et al. 2001; Perez-Elias et al. 2014; Lee et al. 2015; Law et al. 2015) Pregnancy does not influence CD4 count or progression (Allegro et al. 1997) Women have lower serum CRP, scd14 and LPS than men (Mathad et al. J AIDS 2016)
7 START Study START Study Design HIV-positive ART-naïve individuals with CD4 count >500 cells/µl Immediate ART Group Initiate ART immediately following randomization N=2,326 Randomisation Stratified by clinical site Deferred ART Group Defer ART until CD4+ count declines to <350 cells/mm 3 or AIDS N=2,359 Primary composite endpoint, target = 213 Serious AIDS or death from AIDS Serious Non-AIDS Events and death not attributable to AIDS -CVD, ESRD, decompensated liver disease, & non-aids defining cancers
8 START Study START: Recruitment Sites START around the world Women: Recruited 12579/4/2009 (27%) to 23/12/ (11%) 1,539 (33%) 356 (8%) 1,174 (25%) 1,000 (21%) 109 (2%) 35 countries and 215 sites 2530 (54%) from low- and middle-income countries
9 START: Primary End-Point by Subgroup Primary End Point for Subgroups
10 START: Summary 1.8% of participants in the immediate vs. 4.1% in the deferred arm experienced the primary outcome Serious AIDS Events, Serious Non-AIDS Events, or Death 57% reduction in risk Evident for both AIDS and Serious Non-AIDS, greater for Serious AIDS Events, TB and cancer - most events occurred at high CD4 counts Consistent regardless of age, gender, race, region of the world, CD4 count, and viral load at entry Gender differences generally not analysed and reported apart from overall primary START outcome and a BMD sub-study Only 3% post-menopausal women in BMD analysis
11 Questions about Starting Treatment When to start: At the time of HIV diagnosis regardless of CD4 count and when the individual understands the goals of treatment and is ready to start
12 When to START Differences Gender in Differences Efficacy of ART in Efficacy between of men ART and wome Soon et al. AIDS Patient Care & STDs 2012
13 % with VL <50 cps/ml HIV-Positive Women in Germany 2015 vs Multicentre analysis On ART Virological suppression Knecht et al. 6 th International Workshop on HIV & Women 2016
14 UK ASTRA Cohort: Factors Associated with Virological Suppression after >6 Months of ART Women MSW MSM p=0.003 UK born/ not fluent English Non UK born/ fluent English UK Born p=0.16 Depression No Depression p<0.01 0,00 10,00 20,00 % with VL>50 copies/ml p values by Chi squared tests
15 ASTRA Cohort: Key Findings MSW and women compared to MSM more likely to have: detectable viral load viral load rebound after suppression Differences in virological outcomes between MSM and women largely explained by socio-economic circumstances They appear to have less impact for virological differences between MSM and MSW
16 Gender and ART Outcomes: Swiss Cohort 1984 men and 1941 women starting first-line ART Women had lower baseline viral load and higher CD4 counts Women more likely to switch ART or stop treatment in first year of ART, only partly pregnancy driven Lower probability of virological suppression in first 2 years of ART, abated after adjustment for HIV-related and sociodemographic factors Rosin et al. HIV Med 2015
17 Preferred First-Line ART Regimens EACS 2016* DHSS 2016 ABC 3TC DTG TDF FTC DTG TDF FTC RAL TDF FTC EVG/c TAF FTC EVG/c TDF FTC DRV/r TDF FTC RPV HLA-B*5701 negative Pre-treatment estimated CrCl 70 ml/min Pre-treatment estimated CrCl 30 ml/min CD4 count >200 cells and VL <100,000 cps *To be released in Autumn 2016
18 Questions about Selecting Treatment Does gender influence the choice of initial regimen? Does a discussion take place with women about treatment choices in accordance with different life stages and needs?
19 Questions about Selecting Treatment What to consider: Adverse effects of ART Child bearing potential, desire for or likelihood of pregnancy, and safety of ARVs in first trimester (or insufficient data for safety) Choice of contraception and drug-drug interactions
20 Toxicity in women Grade 4 anemia Gender and ART Outcomes CPCRA FIRST study: 55% used AZT, majority pre-menopausal African American women ART discontinuation or changes significantly greater in women for skin rash, neurological symptoms, constitutional symptoms, (and poor adherence) Immune activation and inflammation in women After 48 wks of ART, women have higher γifn and TNFα than men Tedaldi et al. J AIDS 2008; Mirjam-Colette et al. J AIDS 2009; Mathad et al. J AIDS 2016
21 Superior Efficacy of Dolutegravir/Abacavir/Lamivudine FDC Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine FDC in Treatment-Naive Women With HIV-1 Infection: ARIA Study C. Orrell, 1 D. Hagins, 2 E. Belonosova, 3 N. Porteiro, 4 S. Walmsley, 5 V. Falcó, 6 C. Man, 7 A. Aylott, 8 A. Buchanan, 7 B. Wynne, 9 C. Vavro, 7 M. Aboud, 10 K. Smith 7 1 Desmond Tutu HIV Foundation, Cape Town, South Africa; 2 Chatham County Health Department, Savannah, GA, USA; 3 Orel Regional Center for AIDS, Orel, Russia; 4 Fundación IDEAA, Buenos Aires, Argentina; 5 University Health Network, Toronto, Canada; 6 Hospital Vall d Hebron, Barcelona, Spain; 7,9,10 ViiV Healthcare, 7 Research Triangle Park, NC, USA; 9 Philadelphia, PA, USA; 10 Brentford, UK; 8 GlaxoSmithKline Stockley Park, UK 21st International AIDS Conference, July 2016, Durban, South Africa
22 ARIA: DTG/ABC/3TC vs. ATV/r + TDF/FTC Open-label randomised non-inferiority phase 3b study Open-label, randomized 1:1 DTG/ABC/3TC FDC ATV/r +TDF/FTC FDC DTG/ABC/3TC FDC Continuation phase Randomization Week 48 primary analysis Key eligibility criteria: women, ART-naive, HLA-B*5701 negative, HIV-1 RNA >500 c/ml, hepatitis B negative Stratification: by HIV-1 RNA ( or >100,000 copies/ml), CD4+ count ( or >350 cells/mm 3 ) Women who became pregnant were withdrawn and, if possible, offered entry into a DTG/ABC/3TC pregnancy study Primary endpoint: proportion with HIV-1 RNA <50 c/ml at Week 48 using the FDA snapshot algorithm (-12% non-inferiority margin) 21st International AIDS Conference, July 2016, Durban, South Africa Orrell et al. AIDS 2016; Durban, South Africa.
23 Number of subjects Global Enrollment N=499 randomized Country 21st International AIDS Conference, July 2016, Durban, South Africa
24 HIV-1 RNA <50 c/ml, % Snapshot Outcomes at Week 48: ITT-E and PP Populations Virologic outcomes Treatment differences (95% CI) DTG/ABC/3TC (ITT-E, n=248) ATV/r+TDF/FTC (ITT-E, n=247) DTG/ABC/3TC (PP, n=230) ATV/r+TDF/FTC (PP, n=225) ATV/r+TDF/FTC DTG/ABC/3TC , ITT-E (primary) , PP 20 0 Virologic success Virologic non-response 8 13 No virologic data DTG/ABC/3TC is superior to ATV/r+TDF/FTC at Week 48, P=0.005 CI, confidence interval; ITT-E, intent-to-treat exposed; PP, per protocol. 21st International AIDS Conference, July 2016, Durban, South Africa
25 HIV-1 RNA <50 c/ml, % Snapshot Outcomes by Baseline Randomization Strata at Week 48: ITT-E 100 DTG/ABC/3TC (n) ATV/r+TDF/FTC (n) ATV regimen Overall 100,000 >100, >350 HIV-1 RNA c/ml CD4+ count cells/mm 3 ITT-E, intent-to-treat exposed. 21st International AIDS Conference, July 2016, Durban, South Africa
26 Treatment Emergent Mutations in Patients with Confirmed Virologic Withdrawal The resistance analysis was performed on subjects meeting confirmed virologic withdrawal (confirmed 400 c/ml on or after Week 24) Resistance Analysis DTG/ABC/3TC (n=6) ATV/r +TDF/FTC (n=4) INSTI 0 0 NRTI 0 * 1 M184V 0 1 PI 0 0 * Two subjects receiving DTG/ABC/3TC had either K219K/Q (TAM) or E138E/G at CVW with no reduced susceptibility to DTG/ABC/3TC. K219K/Q is not selected for by ABC or 3TC nor does it affect their fold change No subject receiving DTG/ABC/3TC developed INSTI or ABC/3TC resistanceassociated mutations INSTI, integrase strand transfer inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. Orrell et al. AIDS 2016; Durban, South Africa. Slides THAB0205LB. 21st International AIDS Conference, July 2016, Durban, South Africa
27 Summary of Adverse Events: Randomized Phase (up to Week 48) DTG/ABC/3TC (n=248) ATV/r+TDF/FTC (n=247) Any adverse event, n (%) 195 (79%) 197 (80%)* Grade 2 to 4 AE 115 (46%) 137(55%) Drug-related AE (occurring 5% of subjects in either arm) 83 (33%) 121 (49%) Nausea 31 (13) 35 (14) Diarrhoea 12 (5) 18 (7) Dyspepsia 4 (2) 15 (6) Ocular icterus 0 18 (7) Headache 5 (2) 14 (6) Jaundice 0 13 (5) Serious AE 12 (5%) 20 (8%) Fatal AE Drug-related SAE 0 3 (1%) Discontinuations due to AEs 10 (4%) 17 (7%) *Additional AEs identified post-hoc for two ATV+RTV+TDF/FTC subjects at one site are not included in this table. AEs were not considered to impact overall safety findings + Death certificate noted death due to natural causes. Investigator deemed event unrelated to study drug. AE, adverse event; SAE, serious adverse event. 21st International AIDS Conference, July 2016, Durban, South Africa
28 Conclusions In treatment-naive women, DTG/ABC/3TC was superior to ATV/r+TDF/FTC at 48 weeks Difference driven by lower rate of virological non-response and fewer discontinuations due to AEs in DTG arm DTG/ABC/3TC had a favorable safety profile Similar to overall safety profile for DTG from previous studies No treatment-emergent primary INSTI or ABC/3TC resistance mutations in the DTG/ABC/3TC group AE, adverse event; CI, confidence interval; INSTI, integrase strand transfer inhibitor 21st International AIDS Conference, July 2016, Durban, South Africa Orrell et al. AIDS 2016; Durban, South Africa. Slides THAB0205LB.
29 WAVES: TDF/FTC/EVG/c vs. TDF/FTC + ATV/r for First-Line ART in Women International, randomized, double-blind placebo-controlled phase III trial Wk 48 ART-naïve women egfr 70 ml/min (N=575) TDF/FTC/EVG/c OD (n = 289) TDF/FTC + ATV/r OD (n = 286) Openlabel extension Patients generally well matched at baseline HIV-1 RNA >100,000 cps 24%-25% TDF= Tenofovir DF; FTC= Emtricitabine; EVG/c= Elvitegravir/cobicistat; ATV/r= Atazanavir + ritonavir Squires et al. IAS 2015
30 HIV-1 RNA < 50 cps (%) Virological Outcome at Week 48 TDF/FTC/EVG/c TDF/FTC + ATV/r p=0.03 Virological success Virological failure No data Overall treatment difference 6.5% (95% CI ) FDA snapshot algorithm in intention-to-treat population Squires et al. IAS 2015
31 HIV-1 RNA < 50 cps (%) WAVES: Key Results TDF/FTC/EVG/c TDF/FTC + ATV/r Overall 100,000 > 100,000 HIV-1 RNA (cps/ml) Emergent Resistance EVG/c ATV/r (n = 289) (n = 286) Analysis population 7 12 Resistance mutations 1* 3** *RT D67N/D; ** RT M184V/I No difference in changes from baseline for egfr, spine or hip BMD, LDL and HDL cholesterol, total cholesterol/hdl ratio, and triglycerides Greater increase in total cholesterol with EVG/c Lower rate of discontinuation due to adverse events with EVG/c (2.4% vs. 7.0%) egfr= Estimated glomerular filtration rate BMD= Bone mineral density Squires et al. IAS 2015
32 Success (%) WAVES: Virological Success by Region TDF/FTC/EVG/c TDF/FTC + ATV/r Overall USA Uganda Russia Other *p=0.03; p=0.07 Squires et al. IAS 2015
33 Cumulative VF Probability ACTG A5257: Gender and Racial Disparities in Virological Outcomes of First-Line ART Randomised phase III trial of ATV/r vs. RAL vs. DRV/r each with TDF/FTC Week 96 Unadjusted HR Women vs. Men: 1.4 (95% CI ; P= 0.026) Wk 96 Unadjusted HR Black vs. White: 2.8 (95% CI: ; P <.001) Wk 96 Unadjusted HR Hispanic vs. White: 2.0 (95% CI: ; P =.001) Women Men Black Hispanic White Wks Since Study Entry Wks Since Study Entry ATV/r = Atazanavir + ritonavir; RAL= Raltegravir; DRV/r= Darunavir + ritonavir TDF/FTC= Tenofovir DR/Emtricitabine; HR= Hazard Ratio Ribaudo et al. CROI 2016
34 ACTG A5257: Other Factors Associated with Virological Failure Additional factors associated with increased risk of failure: oyounger age orecent non-adherence o Underweight ohigh pre-art viral load olow income oless education ohistory of IDU Ribaudo et al. CROI 2016
35 Stigma & Adherence in Women Women's Interagency HIV Study ( ) n=1168 Significant association between internalized stigma and sub-optimal selfreported adherence among ethnic minority groups (not observe with non- Hispanic whites) Depressive symptoms Internalised stigma Loneliness Low perceived social support Sub-optimal adherence Turan et al. J Acquir Immune Defic Syndr. 2016
36 How Does Living with HIV Impact on Women s Mental Health? Online survey of respondents from 94 countries Social disadvantages correlated with mental health issues Before diagnosis After diagnosis Depression Self-blame Feeling of rejection A strong sense of isolation Anxiety Anorexia Spiritual isolation Suicidal feelings Harmful use of drugs/alcohol Percentage N= 489 Orza et al. J Int AIDS Soc 2015
37 Multiple Factors Influence Access, Engagement, and Treatment Outcomes in Women Experience or fear of violence Beliefs Isolation Drug dependency Depression Alcohol abuse Mental health vulnerabilities Socioeconomic circumstances Fear of blame Care responsibilities Fear of disclosure Fear of prosecution Food security
38 Conclusions: HIV-Positive Women Multi-faceted interventions are needed to promote access, engagement, outcomes, well-being Psycho-social support as part of comprehensive care Interventions aimed at moderating socioeconomic impact on health outcomes may improve outcomes in women a Research should strive for equity of access Clinical research should include measures of socioeconomic factors Reproductive care and beyond Prepare to address issues relevant to aging population Walcott et al. Cult Health Sex 2015; Kumar et al. J Int AIDS Soc 2015; Amin et al. J Int AIDS Soc. 2015; Loutfy et al. J Int AIDS Soc ; Turan et al. J Acquir Immune Defic Syndr. 2016
39 Thank you
Introduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationThe BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir
The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationDisclosures. University of Modena and Reggio Emilia in Modena, Italy. ViiV, MSD, Johnson & Johnson Gilead. Research Support/P.I. Employee.
Disclosures Research Support/P.I. Employee ViiV, MSD, Johnson & Johnson Gilead University of Modena and Reggio Emilia in Modena, Italy Consultant Major Stockholder Speakers Bureau none Gilead Honoraria
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationStatistical issues in HIV trial design. Andrew Hill Senior Visiting Research Fellow Liverpool University
Statistical issues in HIV trial design Andrew Hill Senior Visiting Research Fellow Liverpool University Type 1 error It is statistically significant! (after 100 different statistical tests) Type 1 error:
More informationViiV Healthcare Investor and Analyst Update 24 July 2018
ViiV Healthcare Investor and Analyst Update 24 July 2018 Cautionary statement regarding forward looking statements This presentation may contain forward-looking statements. Forward-looking statements give
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Atazanavir () Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationOptimizing ARV For Women
Optimizing ARV For Women Kathleen E. Squires, MD W Paul and Ida H Havens Professor of Infectious Diseases Director, Division of Infectious Diseases Sidney Kimmel Medical College of Thomas Jefferson University
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya Gilead Sciences Canada, Inc.) Indication: HIV-1 Infection Recommendation:
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationResearch Article Efficacy of Once Daily Darunavir/Ritonavir in PI-Na\ve, NNRTI-Experienced Patients in the ODIN Trial
AIDS Research and Treatment Volume 2015, Article ID 962574, 6 pages http://dx.doi.org/10.1155/2015/962574 Research Article Efficacy of Once Daily Darunavir/Ritonavir in PI-Na\ve, NNRTI-Experienced Patients
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationUnmet needs and challenges of current ART in South Africa. Michelle Moorhouse 21 Nov 2015
Unmet needs and challenges of current ART in South Africa Michelle Moorhouse 21 Nov 2015 SA Snapshot Òct 2015 6-7 million HIV-positive: 18% world total, 25% of Southern Africa 3.2 on first line ART: consume
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More information